{"id":"W3009722442","doi":"10.1200/jco.2007.25.18_suppl.4028","title":"Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Oxaliplatin; Medicine; FOLFOX; Capecitabine; Bevacizumab; Internal medicine; Oncology; Regimen; Colorectal cancer; Chemotherapy; Fluorouracil; Chemotherapy regimen; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008811241,0.0003020407,0.004124316,0.0005311447,0.00004514119,0.00001153489,0.0001885874,0.0004269188,0.0006869925],"category_scores_gemma":[0.005447248,0.0001856083,0.0004857176,0.0006486967,0.0003538301,0.0001603998,0.00003958305,0.001423437,0.000007946927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008060448,"about_ca_system_score_gemma":0.002904888,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001364348,"about_ca_topic_score_gemma":0.02189419,"domain_scores_codex":[0.9920676,0.001233865,0.005355511,0.0003977427,0.0004905136,0.0004548038],"domain_scores_gemma":[0.9789698,0.01712635,0.002945512,0.000151441,0.0004113199,0.0003955545],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9201866,0.02090001,0.0009740997,0.0000118872,0.001321272,0.003638889,0.0006806276,0.00009856562,0.0001314387,0.00001358127,0.001275961,0.05076703],"study_design_scores_gemma":[0.9311267,0.04986046,0.00880911,0.0002001078,0.002026053,0.00009543815,0.00009422768,0.000867558,0.0003697432,0.0001524922,0.006221583,0.0001765826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848546,0.0003771154,0.0002317261,0.009589776,0.002069829,0.002357722,0.00004386374,0.00001619688,0.0004591052],"genre_scores_gemma":[0.9944268,0.001208799,0.001649431,0.00109466,0.001134156,0.00006326462,0.0001304206,0.00002899133,0.0002635134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05059045,"threshold_uncertainty_score":0.9959537,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1315895413467038,"score_gpt":0.5133118688873759,"score_spread":0.3817223275406721,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}